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EAR/EYE/SKIN DISEASES OR DISORDERS
EAR/EYE/SKIN DISEASES OR DISORDERS—Cost Studies
PES4
COST-UTILITY OF COCHLEAR IMPLANTS A SOCIETAL
PERSPECTIVE ANALYSIS
Barlev A, Hay JW
University of Southern California, Los Angeles, CA, USA
OBJECTIVE: To perform a cost-utility (Cost per QALY) analy-
sis of cochlear implants from a societal perspective. METHODS:
Model parameters were based upon literature review of Medline
citations. Costs included direct and lifetime maintenance costs,
costs of special education and caregiver support costs. Medical
costs were inﬂated to year 2003 using the medical component of
the CPI. All cost and outcomes were converted to year 2003
values using a base case annual discount rate of 3%. Cost of
treating bacterial meningitis and its complications was included
in the model following a recent FDA warning. The Health Utility
Index Mark III was used to measure utility changes. The ﬁrst
two years post implantation are not included in the utility cal-
culations, reﬂecting patient efforts in adapting to the device.
RESULTS: Including savings on special education, support 
and caregivers time for a child at age 5 who receives cochlear
implants there is a net societal savings of $73,000 over a child’s
lifetime. Lifetime utility gains for a child age ﬁve or less were
0.39 and for all other ages 0.22. For a child age 5 the lifetime
QALYs gained using a 3% discount is 11.47. One way sensitiv-
ity analyses were performed on model parameters. Ranges were
selected based on the high and low values from the studies
included in the analysis. Based on sensitivity analysis the results
remain very favorable with the range of savings to society for
the base case of $44,000–$102,000. CONCLUSION: Cochlear
implant is a dominant strategy from the societal perspective. The
beneﬁt is maximized when the procedure is done before age 5.
Unfortunately, not everyone with hearing loss can beneﬁt from
the procedure and it is difﬁcult to adapt to and maintain the
device.
PES5
THE COST-EFFECTIVENESS OF OTOTOPICAL
CIPROFLOXACIN AND DEXAMETHASONE VERSUS
OTOTOPICAL OFLOXACIN FOR THE TREATMENT OF
OTORRHEA IN PATIENTS WITH TYMPANOSTOMY TUBES
Roland P1, Waycaster C2
1University of Texas Southwestern Medical Center, Dallas,TX; 2Alcon
Labs Inc, Fort Worth,TX, USA
OBJECTIVES: Otorrhea is a common complication of acute
otitis media in patients with tympanostomy tubes. The goal 
of this research was to determine the cost-effectiveness of
ciproﬂoxacin 0.3%/dexamethasone 0.1% (CD) combination otic
suspension relative to oﬂoxacin 0.3% otic solution (OFX) for
the treatment of otorrhea. METHODS: A decision-analytic
model emulated the ototopical treatment of otorrhea in patients
with tympanostomy tubes. The economic outcome was the cost
per otorrhea free day (OFD) achieved per episode of care. A clin-
ical algorithm was developed which used three tiers of antimi-
crobial otorrhea therapy. Each successive tier of the model
represented the re-treatment of clinical failures from the preced-
ing tier. First tier therapy compared CD & OFX and used
outcome measures taken from a randomized clinical trial (n =
599). Second tier therapy modeled the use of amoxicillin and
clavulanic acid (ACA) with the outcome measures taken from
the medical literature. Third tier therapy was modeled as being
pathogen speciﬁc and could follow one of three separate path-
ways: 1) intramuscular ceftriaxone; 2) oral ﬂuconazole; and 3)
hospitalization and administration of intravenous antibiotics.
Third tier outcomes were based on expert opinion. All patients
were considered cured upon completion of the clinical algorithm.
Cost information was taken from reference sources and pre-
sented from a payer perspective. The model timeline was 31
days. RESULTS: The estimated cost of otorrhea therapy was
$237.70 for the CD pathway and $255.60 for the OFX pathway.
The estimated number of OFDs per episode of care was 25.4 for
the CD pathway and 23.0 for the OFX pathway. The cost-
effectiveness ratios for CD and OFX therapies were $9 and $11
respectively. CONCLUSIONS: CD was both more effective and
less costly than OFX for the treatment of otorrhea in patients
with tympanostomy tubes. Therefore, CD was the dominant
treatment between the two ototopical alternatives.
PES6
PATIENT-REPORTED IMPACT OF AGE-RELATED 
MACULAR DEGENERATION
Schmier JK1, Halpern MT1, Covert D2
1Exponent, Alexandria,VA, USA; 2Alcon Labs, Forth Worth,TX, USA
OBJECTIVE: To assess the patient-reported use of caregiving,
assistive devices and services among individuals with age-related
macular degeneration (AMD) and evaluate the impact of visual
impairment level on this use. METHODS: A new instrument, the
AMD Health and Impact Questionnaire, was developed and
pilot-tested for face validity and comprehensiveness. Following
revisions, the survey was published on the Macular Degenera-
tion Partnership’s website. The study was approved by a central
IRB and respondents provided consent before completing the
survey. Responses were analyzed by category of visual impair-
ment as determined by scores from the Visual Function Ques-
tionnaire near and distance scales (none/mild ≥ 68, moderate =
43.6 to 67, severe £43.5). De-identiﬁed data were analyzed in
SAS. RESULTS: Of 443 respondents, 39% were male and the
mean age was 65 years. Respondents with mild visual impair-
ment comprised 42% of the population, moderate and severe
groups comprised 31% and 27%, respectively. Three-fourths of
the population had AMD in both eyes. Use of paid and unpaid
help was signiﬁcantly associated with severity; 10%, 20%, and
71% of the mild, moderate, and severe respondents reported
caregiver assistance (p < 0.0001). Less than 11% of the respon-
dents used assistive services (e.g., counseling, rehabilitation), but
use was signiﬁcantly higher as severity increased (p < 0.05). For
example, less than 6% of respondents with mild impairment but
almost 77% of the most impaired respondents used counseling
services. Use of devices (cane, magniﬁers, computer software)
also increased with severity (mean of 1.3, 2.1, and 3.8 devices
used, p < 0.0001). Using standard costs for devices and services
and a national average for caregiver time, annual costs for mild,
moderate, and severe respondents were $1902, $3553, and
$20,570, respectively. CONCLUSION: There are substantial dif-
ferences in service and device use with increased AMD severity.
Delaying progression of AMD could result in considerable cost
savings.
PES7
A COST-EFFECTIVENESS ANALYSIS OF TREATING OPEN
ANGLE GLAUCOMA
Malone DC1,Ward S2, Gesser K3
1University of Arizona,Tucson, AZ, USA; 2Royal Danish School of
Pharmacy, Copenhagen, Denmark; 3The Royal Danish School of
Pharmacy, Copenhagen, Denmark
Glaucoma is a chronic ophthalmic disease and untreated leads
to progressive loss of vision. OBJECTIVES: The purpose of this
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study was to perform a cost-effectiveness analysis of ﬁrst-line
monotherapy medications for the treatment of glaucoma.
METHODS: This study was a cost-effectiveness analysis of
latanoprost, brimonidine and beta-blockers for treatment of
glaucoma. Data for the study came from a VA medical center.
Patients were eligible if they had a prescription for latanoprost,
brimonidine or beta-blockers as monotherapy for glaucoma. The
outcomes of interest were change and percent change in intraoc-
ular pressure (IOP). The perspective of the analysis was from that
of a VA medical center and included direct medical costs.
RESULTS: A total of 318 eyes were evaluated, 78 receiving 
beta blockers, 34 receiving brimonidine, and 206 receiving
latanoprost. The majority of patients were white males and the
mean age was 73 years. Patients receiving latanoprost had a
mean(SD) IOP reduction of 7.59(4.6)mmHg compared to
6.8(5.0)mmHg for beta-blockers (p = 0.18), and there was no
signiﬁcant difference was observed between the mean for bri-
monidine (7.1(4.7)mmHg) and beta-blockers (p = 0.76). The
mean percent change in IOP was identical for latanoprost and
brimonidine (29.6%), but only 24.8% for those receiving beta-
blockers. Average (SD) daily cost was $0.05(0.09) for beta-
blockers, $0.29(0.39) for brimonidine, and $0.30(0.42) for
latanoprost (p < 0.001). However, the most cost-effective agent
was brimonidine, with a daily cost of $7.15 for each percent
reduction in IOP. Latanoprost demonstrated a daily cost per
percent IOP reduction of US$7.58. Both brimonidine and
latanoprost were more cost-effective than the beta-blockers with
a cost-effectiveness ratio of US$8.42. The incremental cost-
effectiveness of using brimonidine or latanoprost compared to
beta-blockers was $3.23 and $5.05, respectively. CONCLU-
SIONS: The results suggest that despite a much lower cost, beta-
blockers are not more cost-effective than brimonidine or
latanoprost.
PES8
ECONOMIC RESOURCES UTILIZED IN A COHORT OF
PATIENTS WITH AGE-RELATED MACULAR DEGENERATION
(AMD)
Sharma S1, Dugar A2, Bakal J1, Brown G3, Shah G4
1Queen’s University, Kingston, ON, Canada; 2Pﬁzer Global
Pharmaceuticals, Pﬁzer, Inc, New York, NY, USA; 3Wills Eye Hospital,
Philadelphia, PA, Philadelphia, PA, USA; 4Barnes Retina Institute, St.
Louis, MO, USA
OBJECTIVE: To determine the economic resources utilized in a
cohort of patients with age-related macular degeneration.
METHODS: An Institutional Review Board-approved, resource
utilization study determined the economic resources used by a
cohort of AMD patients over a historical 12-month period from
the societal perspective. We evaluated costs by administering an
interviewer-administered questionnaire and reviewing partici-
pants’ clinic charts. From these two data sources, we evaluated
both direct medical costs and direct non-medical costs (such as
home support and assessment and low vision rehabilitation
including CCTV magniﬁers). Indirect costs incurred by family
members related to medical visits and supportive care were eval-
uated; productivity was not evaluated due to the low employ-
ment rate in this demographic. Statistical analyses included
determining the mean and variance about the main cost drivers.
In addition, a series of multivariate models evaluated if visual
dysfunction and other clinical variables were associated with
economic resources utilized. RESULTS: The 41 subjects included
in this analysis had a mean age of 79.6 years (SD 6.1); 64% were
females. Seventy-four percent of the sample had wet AMD, and
38.4% of the sample had bilateral wet disease. The median dura-
tion of disease was 16.9 months. The mean logMAR visual
acuity of the sample was 0.51 in the better seeing eye (20/65)
and 1.17 in the worse seeing eye (20/300). The mean annual cost
per patient in this sample was $3944.62 (CND). Direct medical
costs were the main cost driver, accounting for 91% ($3605) of
total costs. Multivariate linear regression using stepwise variable
selection demonstrated that both duration (p = 0.02) and visual
acuity in the better-seeing eye (p = 0.05) were signiﬁcantly asso-
ciated with increasing consumption of direct non-medical
resources. CONCLUSIONS: The economic resources utilized by
AMD patients are high, and visual acuity in the better-seeing eye
is inversely related to direct non-medical costs.
PES9
ELIGIBILITY, UTILIZATION,AND COSTS IN A CALIFORNIA
MEDICAID LUPUS POPULATION
Nichol MB1, Knight TK1, Shi S1,Wallace DJ2,Weisman MH3
1University of Southern California, Los Angeles, CA, USA; 2University
of California, Los Angeles, CA, USA; 3Cedars-Sinai Hospital, Los
Angeles, CA, USA
OBJECTIVES: To investigate whether ethnicity was associated
with differences in Medicaid eligibility, health care utilization,
and direct medical costs over time in a systemic lupus erythe-
matosus (SLE) population. METHODS: A retrospective analysis
of California Medicaid claims data was conducted on patients
with a diagnosis of SLE. The patient monitoring period spans a
7-year (84 month) timeframe. Patient eligibility and month-by-
month utilization and costs were computed and compared across
ethnic groups. Descriptive statistics are presented with ﬁgures or
tables detailing activity during the monitoring period. A mixed
regression model on patient-level data was used to verify the
trends of the aggregate data, controlling for covariates.
RESULTS: Hispanic patients have shorter eligibility compared to
other cohorts (about 50% vs. 70% remain eligible at Month 36,
respectively). Over time, Hispanics generated lower total costs
than other cohorts. Results for inpatient frequency, prescription
costs and outpatient/physician/supply costs followed similar pat-
terns. Mixed regression model ﬁndings revealed that when
adjusted for age, gender and aid program, total costs for His-
panic patients decreased as the length of care increased, in con-
trast to the experience of other ethnic groups. The interaction
between ethnicity and treatment progression measured by
quarter was signiﬁcant (p < 0.0001), but ethnicity as a main
effect was not (p = 0.091). Differences in total costs appear small
initially, but as the follow-up period gets longer, Hispanic
patients experience lower total costs. CONCLUSIONS: These
preliminary longitudinal data in a single state Medicaid program
may imply that Hispanics with lupus either have slower disease
progression than other ethnic groups, are able to return to work
faster, or have difﬁculties with access to care.
PES10
THE COST-EFFECTIVENESS OF METHYL AMINOLEVULINATE
PHOTODYNAMIC THERAPY (MAL-PDT) FOR DIFFICULT TO
TREAT ACTINIC KERATOSES
Orme ME, Howard P
Heron Evidence Development, Letchworth, Herts, United Kingdom
OBJECTIVES: Methyl aminolevulinate cream is the ﬁrst licensed
topical PDT product in the UK to treat actinic keratoses (AK).
It is activated when the cream is illuminated with a red light
source (MAL-PDT). In the UK, the incidence rate of AK is 5%.
The aim of this study was to assess the cost-effectiveness of
MAL-PDT versus the most commonly used intervention,
cryotherapy. METHODS: Clinical outcomes were obtained from
a multicentre comparative trial of difﬁcult to treat AK (Foley et
al. Journal of Dermatol Treat (2003)), deﬁned as thin or non-
hyperkeratotic AK on the face or scalp. Resource use was from
a Delphi panel of dermatologists and costs from standard UK
